VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome
VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the efficacy and safety of apraglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog, in treating patients with Short Bowel Syndrome (SBS) with intestinal failure (SBS-IF). The STARS trial marks the largest phase […]